These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

129 related items for PubMed ID: 8071686

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Transient cranial neuropathy in prostatic cancer with bone metastases after rhenium-186-HEDP treatment.
    de Klerk JM, Zonnenberg BA, Krouwer HG, Blijham GH, van Dijk A, van het Schip AD, van Die J, van Rijk PP.
    J Nucl Med; 1996 Mar; 37(3):465-7. PubMed ID: 8772646
    [Abstract] [Full Text] [Related]

  • 5. Dosage and response in radiopharmaceutical therapy of painful osseous metastases.
    Silberstein EB.
    J Nucl Med; 1996 Feb; 37(2):249-52. PubMed ID: 8667054
    [No Abstract] [Full Text] [Related]

  • 6. Dosimetry of 188Re-hydroxyethylidene diphosphonate in human prostate cancer skeletal metastases.
    Liepe K, Hliscs R, Kropp J, Runge R, Knapp FF, Franke WG.
    J Nucl Med; 2003 Jun; 44(6):953-60. PubMed ID: 12791825
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Dose escalation study of rhenium-186 hydroxyethylidene diphosphonate in patients with metastatic prostate cancer.
    de Klerk JM, Zonnenberg BA, van het Schip AD, van Dijk A, Han SH, Quirijnen JM, Blijham GH, van Rijk PP.
    Eur J Nucl Med; 1994 Oct; 21(10):1114-20. PubMed ID: 7530199
    [Abstract] [Full Text] [Related]

  • 9. Evaluation of toxicity and efficacy of 186Re-hydroxyethylidene diphosphonate in patients with painful bone metastases of prostate or breast cancer.
    Kolesnikov-Gauthier H, Carpentier P, Depreux P, Vennin P, Caty A, Sulman C.
    J Nucl Med; 2000 Oct; 41(10):1689-94. PubMed ID: 11037999
    [Abstract] [Full Text] [Related]

  • 10. Can bone marrow scintigraphy predict platelet toxicity after treatment with 186Re-HEDP?
    de Klerk JM, Zonnenberg BA, van Het Schip AD, van Dijk A, Huiskes AW, van Rijk PP.
    Nucl Med Commun; 1999 Sep; 20(9):833-6. PubMed ID: 10533189
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Treatment of metastatic bone pain using the bone seeking radiopharmaceutical Re-186-HEDP.
    De Klerk JM, Zonnenberg BA, Blijham GH, Van Het Schip AD, Hoekstra A, Han SH, Quirijnen JM, Van Dijk A, Van Rijk PP.
    Anticancer Res; 1997 Sep; 17(3B):1773-7. PubMed ID: 9179233
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Rhenium-186(Sn)HEDP for treatment of painful osseous metastases: results of a double-blind crossover comparison with placebo.
    Maxon HR, Schroder LE, Hertzberg VS, Thomas SR, Englaro EE, Samaratunga R, Smith H, Moulton JS, Williams CC, Ehrhardt GJ.
    J Nucl Med; 1991 Oct; 32(10):1877-81. PubMed ID: 1717669
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. [Palliation of bone pain in metastatic prostate carcinoma. Value of radionuclide therapy with rhenium 186 HEDP].
    Klutmann S, Bohuslavizki KH.
    MMW Fortschr Med; 1999 Nov 04; 141(44):38-9. PubMed ID: 10912142
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Introduction of a new semi-quantitative index with predictive implications in patients with painful osseous metastases after (186)Re-HEDP therapy.
    Zafeirakis A, Zissimopoulos A, Baziotis N, Limouris GS.
    Q J Nucl Med Mol Imaging; 2011 Feb 04; 55(1):91-102. PubMed ID: 21068716
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.